ENT-Research GmbH
- Address
- Bocholder Str. 2, 45355 Essen, Germany
ENT-Research GmbH - Hearing Loss Research Center
ENT-Research GmbH is a specialized clinical research facility dedicated to advancing the treatment of otolaryngological conditions, with particular expertise in acute auditory disorders. The center focuses on innovative therapeutic approaches for sudden hearing loss, conducting rigorous comparative efficacy studies that evaluate novel drug delivery methods against established treatment protocols.
- Idiopathic Sudden Sensorineural Hearing Loss (ISSNHL) treatment interventions
- Novel intratympanic drug delivery systems and middle ear injection therapies
- Comparative effectiveness research between systemic and localized otic treatments
The research center specializes in evaluating pure tone audiometry outcomes and hearing threshold improvements in patients with moderately-severe to profound hearing loss. Their clinical trials examine both safety and tolerability profiles of experimental treatments while comparing them to standard oral steroid regimens, contributing valuable evidence to optimize therapeutic strategies for acute auditory emergencies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 1 of 2 therapeutic areas and 15 of 39 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Inmunotek S.L.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in ENT-Research GmbH
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy of a polymerized mannan‑conjugated Phleum pratense and Dactylis glomerata allergoid vaccine in patients with grass‑pollen allergic rhinitis/rhinoconjunctivitis | Inmunotek S.L. | Phase IV | Not Recruiting | Jun 2026 | — |
IMP list
lock Showing 1 of 39 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Azelastine Hydrochloride | 2 | Unknown | 2024-10-28 | 2026-06-01 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.